Clinical Oncology
Volume 19, Issue 3 , Pages 204-208 , April 2007

CD117 (c-kit) Expression in Human Hepatocellular Carcinoma

  • G. Becker

      Affiliations

    • Department of Medicine II, Freiburg University Hospital, Freiburg, Germany
    • Corresponding Author InformationAuthor for correspondence: G. Becker, Department of Medicine II, University Hospital Freiburg, Hugstetter Strasse 55, D-79106 Freiburg, Germany. Tel: +49(0)7612703213; fax: +49(0)7612703291.
    • ,
  • A. Schmitt-Graeff

      Affiliations

    • Institute of Pathology, Freiburg University Hospital, Freiburg, Germany
    • ,
  • V. Ertelt

      Affiliations

    • Institute of Pathology, Freiburg University Hospital, Freiburg, Germany
    • ,
  • H.E. Blum

      Affiliations

    • Department of Medicine II, Freiburg University Hospital, Freiburg, Germany
    • ,
  • H.-P. Allgaier

      Affiliations

    • Department of Medicine II, Freiburg University Hospital, Freiburg, Germany

Received 12 August 2006 ,Revised 5 December 2006 ,Accepted 14 December 2006.

References 

  1. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19:271–285
  2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–750
  3. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg. 1993;218:145–151
  4. Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228:235–240
  5. CLIP Group (Cancer of the Liver Italian Programme) . Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet. 1998;352:17–20
  6. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut. 1998;42:442–447
  7. Yuen MF, Poon RT, Lai CL, et al. A randomised placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology. 2002;36:687–691
  8. Allgaier HP, Becker G, Olschewski M, Zähringer A, Blum HE. Octreotide treatment in patients with advanced hepatocellular carcinoma: first results of the randomized placebo-controlled double-blind HECTOR trial. Hepatology. 2003;38(Suppl 1A):1243
  9. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;326:1907–1917
  10. Llovet JM, Bruix J. Systematic review of randomized controlled trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–442
  11. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular kinase domain mutations in gastrointestinal tumors. Am J Pathol. 2000;156:791–795
  12. Toyota M, Hinoda Y, Takaoka A, et al. Expression of c-kit and kit ligand in human colon carcinoma cells. Tumour Biol. 1993;14:295–302
  13. Jeng YM, Lin CY, Hsu HC. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett. 2000;154:107–111
  14. Strohmeyer T, Peter S, Hartmann M, et al. Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. Cancer Res. 1991;51:1811–1816
  15. Cohen PS, Chan JP, Lipunskaya M, Biedler JL, Seeger RC. Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group. Blood. 1994;84:3465–3472
  16. Chung CY, Yeh KT, Hsu NC, et al. Expression of c-kit protooncogene in human hepatocellular carcinoma. Cancer Lett. 2005;217:231–236
  17. Went PT, Dirnhofer S, Bundi M, et al. Prevalence of KIT expression in human tumors. J Clin Oncol. 2004;22:4514–4522
  18. Savage DG, Antman KH. Imatinib mesylate – a new oral targeted therapy. N Engl J Med. 2002;346:683–693
  19. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001;358:1421–1423
  20. Druker B. Signal transduction inhibition. Results from phase I trials in chronic myeloid leukaemia. Semin Hematol. 2001;38:9–14
  21. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukaemia. N Engl J Med. 2002;346:645–652
  22. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 2002;3:655–664
  23. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480
  24. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052–1056
  25. Eckel F, von Delius S, Mayr M, et al. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncology. 2005;69:363–371
  26. Schmitt-Gräff A, Ertelt V, Allgaier HP, et al. Cellular retinol-binding protein-1 in hepatocellular carcinoma correlates with β-catenin, Ki-67 index and patient survival. Hepatology. 2003;38:470–480
  27. Tsou AP, Wu KM, Tsen TY, et al. Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression pattern characteristic of human hepatocellular carcinoma. Genomics. 1998;50:331–340
  28. Arber DA, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD117) in human tissues. Value in the diagnosis of mast cell disorders. Hum Pathol. 1998;29:498–504
  29. Lammie A, Drobnjak M, Gerald W, Saad A, Cote R, Cordon-Cardo C. Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem. 1994;42:1417–1425
  30. Tsuura Y, Hiraki H, Watanabe K, et al. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human. Immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch. 1994;424:135–141
  31. Natali PG, Nicotra MR, Sures I, Santoro E, Bigotti A, Ullrich A. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res. 1992;52:6139–6143
  32. Matsuda R, Takahashi T, Nakamura S, et al. Expression of c-kit receptor in human solid tumors and in corresponding fetal and adult normal tissues. Am J Pathol. 1993;142:339–346
  33. Ramadori G, Füzesi L, Grabbe E, Pieler T, Armbrust T. Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis. Anti-Cancer Drugs. 2004;15:405–409
  34. Takayama T, Makuuchi M, Hiroshashi S, et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet. 1990;336:1150–1153
  35. Borzio M, Bruno S, Roncalli M, et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology. 1995;108:812–817
  36. Koike K, Tsutsumi T, Fujie H, Shintani Y, Kyoji M. Molecular mechanism of viral hepatocarcinogenesis. Oncology. 2002;62(Suppl. 1):29–37
  37. Thorgeirsson SS. Progenitor cell tumors in human liver. Liver. 1998;18:227–228
  38. Fang CH, Gong JQ, Zhang W. Function of oval cells in hepatocellular carcinoma in rats. World J Gastroenterol. 2004;10:2482–2487
  39. Potti A, Ganti AK, Tendulkar K, et al. HER-2/neu and CD117 (c-kit) overexpression in hepatocellular and pancreatic carcinoma. Anticancer Res. 2003;23:2671–2674
  40. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–649
  41. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer. 1985;56:918–928
  42. Cancer of the Liver Italian Programme (CLIP) Investigators . A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology. 1989;28:751–755
  43. Cancer of the Liver Italian Programme (CLIP) investigators . Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000;31:840–845
  44. Allgaier HP, Deibert P, Olschewski M, et al. Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection — a single center analysis including 132 patients. Int J Cancer. 1998;79:601–605
  45. Yamamoto K, Masuzawa M, Kato M, et al. Evaluation of combined therapy with chemoembolization and ethanol injection for advanced hepatocellular carcinoma. Semin Oncol. 1997;24(Suppl. 6):50–55
  46. Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol. 2002;117:188–193

PII: S0936-6555(06)00438-9

doi: 10.1016/j.clon.2006.12.009

Clinical Oncology
Volume 19, Issue 3 , Pages 204-208 , April 2007

Article Tools

* Image Usage & Resolution